uniQure N.V. (QURE): Total Assets
$824.91M
As of 2025-12-31
$778.71M
As of 2026-03-31
+5.4%
3-year compound annual growth
+19.4%
5-year compound annual growth
+12.1%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $824.91M | +48.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $556.54M | -33.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $831.69M | +18.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $704.96M | -12.9% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $809.18M | +137.7% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $340.39M | -24.1% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $448.63M | +63.8% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $273.91M | +30.7% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $209.64M | +10.2% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $190.26M | -27.6% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $262.66M | n/a | 2017-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $8.52M | +160.9% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗